Safer, more effective drugs will push vasculitis treatment market value to $558 million by 2024
GlobalData report states that the leading driver of this growth will be the anticipated launches of five biologics for the treatment of various forms of vasculitis, including BMS's Orencia, J&J’s Remicade, GSK’s (GSK) Benlysta and Nucala, and Roche’s Actemra.
The vasculitis treatment market in the US and major European pharmaceutical markets (France, Germany, Italy, Spain, and the UK) is expected to expand in value over the next decade, from under $342 million in 2014 to over $558 million by 2024, at a Compound Annual Growth Rate (CAGR) of 5.1%, according to research and consulting firm GlobalData.
The company’s latest report "OpportunityAnalyzer: Vasculitis – Opportunity Analysis and Forecast to 2024" states that the leading driver of this reasonably robust growth will be the anticipated launches of five biologics for the treatment of various forms of vasculitis, including Bristol-Myers Squibb’s (BMS) Orencia, Johnson & Johnson’s Remicade, GlaxoSmithKline’s (GSK) Benlysta and Nucala, and Roche’s Actemra.
Alexandra Annis, MS, GlobalData’s Analyst covering Immunology, says: “The regulatory approval of these drugs throughout the forecast period will introduce four novel mechanisms of action (MOAs) to the market, which will address current unmet needs well.
“The greatest unmet needs in the vasculitis market are improved safety and efficacy for both induction and maintenance therapies, as induction regimens for the management of vasculitis typically come with a considerable list of side effects.”
GlobalData believes the improved effectiveness and lack of inconvenient side effects that come with the introduction of these new MOAs offer exciting prospects for drug companies.
Annis explains: “The approval of biologics has the potential to result in big profits for pharma, as the cost of using them to treat a patient with vasculitis surpasses $16,000 per year. For this reason, vasculitis is an attractive area for label expansions.”
The analyst adds that Roche’s Actemra, BMS’s Orencia and GSK’s Nucala are anticipated to be the most successful of the new vasculitis treatment market entrants, as they have demonstrated strong efficacy and safety in clinical trials. Despite this, there will be barriers preventing the vasculitis market from reaching its full growth potential during the forecast period.
Annis continues: “The high cost of biologics will limit their uptake, especially in cost-conscious markets that are facing austerity measures. Cheaper biosimilars will challenge established brands.
“In addition, there will be challenges in gaining reimbursement of biologics approved as induction therapies for use as maintenance therapies, such as Rituxan.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance